Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
2 "Keira Herr"
Filter
Filter
Article category
Original Articles
Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials
Hiroshi Nakase, Baili Chen, Qian Cao, Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Dong Il Park, Keira Herr, Bryan Wahking, Wai Chun Yiu, Jianmin Zhuo, Minhu Chen
Received July 22, 2025  Accepted January 12, 2026  Published online May 21, 2026  
DOI: https://doi.org/10.5217/ir.2025.00150    [Epub ahead of print]
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Guselkumab, a dual-acting interleukin-23p19 subunit inhibitor, demonstrated efficacy and safety in participants with moderately to severely active Crohn’s disease in the global phase 3 GALAXI 2 and 3 trials. We report a subgroup analysis in East Asian participants.
Methods
GALAXI 2 and 3 (NCT03466411) are identical, 48-week treat-through trials. Participants were randomized 2:2:2:1 to guselkumab 200 mg IV every 4 weeks (q4w; ×3), followed by 100 mg SC every 8 weeks (q8w) or 200 mg SC q4w; ustekinumab; or placebo. Placebo participants not in clinical response at week (W)12 received ustekinumab. Co-primary endpoints were the composite of clinical response at W12 and clinical remission at W48, and the composite of clinical response at W12 and endoscopic response at W48. This subgroup analysis included participants from China, Japan, South Korea, and Taiwan.
Results
The East Asian subgroup included 192 participants. Rates of clinical response at W12 and clinical remission at W48 with guselkumab were 55.6% (100 mg SC q8w) and 51.0% (200 mg SC q4w) versus 3.1% with placebo. Rates of clinical response at W12 and endoscopic response at W48 with guselkumab were 44.4% (100 mg SC q8w) and 39.2% (200 mg SC q4w), versus 0% for placebo. Numerically higher proportions of guselkumab participants achieved clinical and endoscopic outcomes at W48 relative to ustekinumab. Adverse event rates were consistent with the global population.
Conclusions
Efficacy of guselkumab in East Asian participants was consistent with that observed in the global GALAXI 2 and 3 population. The safety profile was favorable and consistent with previous reports.
  • 3,698 View
  • 99 Download
Close layer
Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the phase 3 GRAVITI study
Wenjia Liu, Hong Guo, Tae Oh Kim, Ken Takeuchi, Tadakazu Hisamatsu, Jennifer Fable, Mobolaji Olurinde, Bryan Wahking, Keira Herr, Jianmin Zhuo, Qian Cao
Received June 23, 2025  Accepted October 2, 2025  Published online February 12, 2026  
DOI: https://doi.org/10.5217/ir.2025.00107    [Epub ahead of print]
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
The GRAVITI (NCT05197049) study demonstrated efficacy and safety of guselkumab, a dual-acting interleukin-23p19 subunit inhibitor, as subcutaneous (SC) induction and maintenance therapy in participants with moderate to severely active Crohn’s disease (CD). We report post hoc subgroup analyses in East Asian participants.
Methods
Seventy-one East Asian participants were randomized 1:1:1 to guselkumab 400 mg SC every 4 weeks (q4w) (x3) followed by 100 mg SC every 8 weeks (q8w) starting at Week 16 (n = 23), guselkumab 400 mg SC q4w (x3) followed by 200 mg SC q4w starting at Week 12 (n = 20), or placebo (n = 28) in the phase 3 double-blind, placebo-controlled, treat-through GRAVITI study. From Week 16, placebo participants meeting rescue criteria were eligible for rescue treatment with guselkumab. Clinical remission at Week 12 and endoscopic response at Week 12 were co-primary endpoints, additional endpoints included Patient-Reported Outcome-2 remission (Week 12), clinical response (Week 12), clinical remission (Week 24 and Week 48), and endoscopic response (Week 48), and safety through Week 48.
Results
Greater proportions of East Asian participants receiving guselkumab 400 mg SC achieved clinical remission versus placebo (41.9% vs. 14.3%) and endoscopic response versus placebo (39.5% vs. 21.4%) at Week 12. At Week 48, greater proportions of participants in both guselkumab groups (100 mg SC q8w, 69.6%; 200 mg SC q4w, 60.0%) achieved clinical remission versus placebo (10.7%) and endoscopic response versus placebo (43.5%, 60.0%; vs. placebo 0.0%). The adverse event profile was generally consistent with the global population.
Conclusions
Efficacy and safety results of SC guselkumab in East Asian participants with moderately to severely active CD reflect findings from the global study.

Citations

Citations to this article as recorded by  
  • Guselkumab in the treatment of inflammatory bowel diseases: A literature review
    O. V. Knyazev
    Meditsinskiy sovet = Medical Council.2026; (15): 135.     CrossRef
  • 4,088 View
  • 162 Download
  • 1 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP